                </a></li></ul></div><p><strong>Figure 5.  <span>Efavirenz is more potent than nevirapine against HIV-1 NL4-3 in SCID-hu Thy/Liv mice.</span></strong></p><a id="article1.body1.sec3.sec3.fig2.caption1.p1" name="article1.body1.sec3.sec3.fig2.caption1.p1"></a><p>Mice were treated by twice-daily oral gavage with nevirapine or efavirenz at the indicated dosage levels beginning on day −1. Antiviral efficacy was assessed by determining HIV-1 RNA (A) and p24 (B), and thymocyte protection was assessed by percentage of DP thymocytes (C) (means±SEM). *p≤0.05, compared with untreated mice for the number of mice indicated under each bar.</p>
<span>THISISTHEEND
